Endogenous calcitonin gene-related peptide in cerebrospinal fluid and early quality of life and mental health after good-grade spontaneous subarachnoid hemorrhage – A feasibility series
Creators: name: Bründl, Elisabeth
name: Proescholdt, Martin
name: Störr, Eva-Maria
name: Schödel, Petra
name: Bele, Sylvia
name: Höhne, Julius
name: Zeman, Florian
name: Brawanski, Alexander
name: Schebesch, Karl-Michael
Publisher: name: Universität Regensburg
Year: 2020
Subjects: subject: DELAYED CEREBRAL-ISCHEMIA; EXTERNAL JUGULAR-VEIN; NEUROPEPTIDE-Y; NEUROPSYCHOLOGICAL OUTCOMES; INTRACRANIAL ANEURYSMS; FOLLOW-UP; CGRP; DEPRESSION; INVOLVEMENT; VASOSPASM; Calcitonin gene-related peptide; CGRP; Health-related quality of life; Impairment; Neuropsychological outcome; Spontaneous subarachnoid hemorrhage
subject: 610 Medizin

description: The vasodilatory calcitonin gene-related peptide (CGRP) is excessively released after spontaneous subarachnoid hemorrhage (sSAH) and modulates psycho-behavioral function. In this pilot study, we prospectively analyzed the treatment-specific differences in the secretion of endogenous CGRP into cerebrospinal fluid (CSF) during the acute stage after good-grade sSAH and its impact on self-reported health-related quality of life (hrQoL). Twenty-six consecutive patients (f:m = 13:8; mean age 50.6 years) with good-grade sSAH were enrolled (drop out 19% (n = 5)): 35% (n = 9) underwent endovascular aneurysm occlusion, 23% (n = 6) microsurgery, and 23% (n = 6) of the patients with perimesencephalic SAH received standardized intensive medical care. An external ventricular drain was inserted within 72 h after the onset of bleeding. CSF was drawn daily from day 1-10. CGRP levels were determined via competitive enzyme immunoassay and calculated as "area under the curve" (AUC). All patients underwent a hrQoL self-report assessment (36-Item Short Form Health Survey (SF-36), ICD-10-Symptom-Rating questionnaire (ISR)) after the onset of sSAH (t(1): day 11-35) and at the 6-month follow-up (t(2)). AUC CGRP (total mean +/- SD, 5.7 +/- 1.8 ng/ml/24 h) was excessively released into CSF after sSAH. AUC CGRP levels did not differ significantly when dichotomizing the aSAH (5.63 +/- 1.77) and pSAH group (5.68 +/- 2.08). aSAH patients revealed a higher symptom burden in the ISR supplementary item score (p = 0.021). Multiple logistic regression analyses corroborated increased mean levels of AUC CGRP in CSF at t(1)as an independent prognostic factor for a significantly higher symptom burden in most ISR scores (compulsive-obsessive syndrome (OR 5.741,p = 0.018), anxiety (OR 7.748,p = 0.021), depression (OR 2.740,p = 0.005), the supplementary items (OR 2.392,p = 0.004)) and for a poorer performance in the SF-36 physical component summary score (OR 0.177,p = 0.001). In contrast, at t(2), CSF AUC CGRP concentrations no longer correlated with hrQoL. To the best of our knowledge, this study is the first to correlate the levels of endogenous CSF CGRP with hrQoL outcome in good-grade sSAH patients. Excessive CGRP release into CSF may have a negative short-term impact on hrQoL and emotional health like anxiety and depression. While subacutely after sSAH, higher CSF levels of the vasodilator CGRP are supposed to be protective against vasospasm-associated cerebral ischemia, from a psychopathological point of view, our results suggest an involvement of CSF CGRP in the dysregulation of higher integrated behavior.